Infant Bacterial Therapeutics AB appoints new CFO
Infant Bacterial Therapeutics AB (publ.) (“IBT”) is pleased to announce the appointment of Daniel Mackey as Chief Financial Officer (CFO) from January 2017 replacing Michael Owens in this role. Michael Owens will continue as financial controller of the company.
Daniel has 20 years experience from diverse U.S. and international management positions in finance and accounting with Investors Bank & Trust Co., Nordea Investment Management AB and Nordea Bank AB. In his role as CFO, Daniel will be responsible for overseeing capital and financing strategies, accounting and investor relations.
- We welcome Daniel to IBT. Our current operational focus is on the on-going US phase-II clinical trial. Next year will hold important new challenges and we are therefore very pleased to have Daniel on board to contribute to the development of IBT, says Staffan Strömberg CEO.
More information about the IBT Team is available on IBT’s website: http://ibtherapeutics.com/about-ibt/the-team/
For additional information please contact
Staffan Strömberg, CEO, phone: +46 8 410 145 55
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 8 410 145 55
Infant Bacterial Therapeutics AB (“IBT”) is a pharmaceutical company based in Stockholm that develops drugs that meet the needs of the premature infants. IBT’s current focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (“NEC”), a fatal disease that affects premature infants. IBT is listed on Nasdaq First North with Erik Penser Bankaktiebolag as Certified adviser.